Arcellx, Inc. (ACLX) Stock

About Arcellx, Inc.

Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.

Arcellx, Inc. is headquartered in US.

Arcellx, Inc. (ACLX) stock trades at $115.07 with a market capitalization of $6.73B. The stock is valued at a negative price-to-earnings (P/E) ratio of -28.27, reflecting a net loss over the last twelve months, price-to-book of 16.10, price-to-sales of 302.09. Over the past 52 weeks the stock has ranged between $50.85 and $115.13, and currently trades at or near its 52-week high.

On profitability, Arcellx, Inc. generates a return on equity (ROE) of -55.42% (negative, reflecting a net loss), return on capital employed of -50.64%, an operating margin of -1150.00%, a net profit margin of -1040.91%.

Official website: arcellx.com

Arcellx, Inc. by the numbers, 2018–2025

Between 2018 and 2025 Arcellx, Inc. reported revenue of $0 rising to $22.0M. Compounded, revenue has grown —% a year over five years, —% over three, -79.6% over the last twelve months. Net profit fell to $-229.0M.

The most recent net margin is -1040.91%. On a trailing twelve-month basis to Dec '25, revenue is $23.0M and net profit $-229.0M.

Borrowings stand at $96.0M, cash on hand is $450.3M, cash from operations was $-210.0M in the latest year, positive in 1 of the last 8.

Return on equity has averaged -26.8% over five years, and was -57.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Arcellx, Inc. (ACLX) — frequently asked questions